Bibliometric Analysis of Global Research Trends in Adverse Drug Reactions in Oral Cancer Treatment: A 30-Year Perspective (1995–2025)

Objective: To analyze the global research landscape of adverse drug reactions in oral cancer treatment through bibliometric analysis, examining publication trends, collaboration networks, and research hotspots from 1995 to 2025. Methods: A comprehensive search was conducted in Web of Science Core Collection and Scopus databases, retrieving 424 publications after deduplication. Bibliometric analysis was performed using VOSviewer 1.6.20 and CiteSpace 6.2R6 to visualize author collaboration networks, institutional cooperation, journal distribution, country contributions, and keyword cooccurrence patterns. Origin 2025 was used for graphical representation of publication trends. Network parameters were analyzed using silhouette index, clustering algorithms, and burst detection techniques. Results: Research output showed a consistent upward trend, with significant acceleration after 2010 and peak production in 2022 (53 publications). China (118 publications), USA (84), and Japan (62) emerged as leading contributors, though citation impact varied considerably across countries. Analysis of 12 major research clusters (silhouette values 0.723–1.000) revealed distinct thematic concentrations, from traditional treatment modalities to emerging approaches like immunotherapy. Keyword burst analysis identified temporal shifts in research focus from risk factors (2001–2005) to treatment modalities (2011–2020) and most recently to advanced therapeutic approaches including nanoparticles and precision medicine (2022–2025). Conclusion: The bibliometric analysis reveals a maturing research landscape in oral cancer drug adverse reactions, characterized by increasing international collaboration and evolution toward more sophisticated treatment paradigms. Recent research emphasis on recurrent disease management, immunotherapy, and nanoparticle-based approaches suggests promising directions for future clinical innovations and improved patient outcomes.